Following publication of the original article [1], the authors reported that they had supplied the incorrect figure for publication.
Cao et al. BMC Cancer (2018) 18:1293.
Anzeige
https://doi.org/10.1186/s12885-018-5205-9
Following publication of the original article [1], the authors reported that they had supplied the incorrect figure for publication. The correct figure is displayed below. The authors apologise for the error.
Fig. 2
miR-18a promotes cell proliferation in EBV-positive lymphoma cells. a miR-18a promoted tumor cell growth in vitro in EBV-positive lymphoma cell lines. CCK-8 cell viability assay was performed after the transfection of miR-18a mimics or miR-18a inhibitor into EBV-positive lymphoma cell lines (P3HR-1, Raji, EBV infected BJAB) and the EBV-negative lymphoma cell line BJAB. The data represented the mean values of five repeats. The data are shown as the means±SD (Student T-test, *p < 0.05). b Flow cytometry analysis of the cell cycle after the transfection of miR-18a. c Cell cycle distribution of cells in S phase. The data were presented as the means±SD of four replicates (Student T-test, *p < 0.05; **p < 0.01)
×
![]()
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.